These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10863101)

  • 1. Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir.
    Reina J; Ballesteros F; Gasco J; Munar M; Mari M
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):83-6. PubMed ID: 10863101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shell-vial culture and pp65 antigenemia assay in the detection of cytomegalovirus in the first blood sample of renal transplant recipients.
    Reina J; Fernandez-Baca V; Saurina J; Blanco I; Munar M
    J Med Virol; 1998 Jul; 55(3):240-2. PubMed ID: 9624613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
    Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
    Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
    Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
    Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients.
    Poirier-Toulemonde AS; Milpied N; Cantarovich D; Morcet JF; Billaudel S; Imbert-Marcille BM
    J Clin Microbiol; 2000 Sep; 38(9):3143-9. PubMed ID: 10970347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.
    Grossi P; Kusne S; Rinaldo C; St George K; Magnone M; Rakela J; Fung J; Starzl TE
    Transplantation; 1996 Jun; 61(11):1659-60. PubMed ID: 8669117
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients.
    Marenzi R; Cinque P; Ceresa D; Racca S; Lillo F; Lazzarin A
    Scand J Infect Dis; 1996; 28(4):347-51. PubMed ID: 8893396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of plasma polymerase chain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients.
    Piiparinen H; Höckerstedt K; Grönhagen-Riska C; Lappalainen M; Suni J; Lautenschlager I
    J Clin Virol; 2001 Aug; 22(1):111-6. PubMed ID: 11418358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.
    Carvalho FR; Cosendey RI; Souza CF; Medeiros T; Menezes PA; Silva AA; Almeida JR; Lugon JR
    Braz J Infect Dis; 2017; 21(1):51-56. PubMed ID: 27888673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of urine and blood cultures for diagnosing cytomegalovirus infection in the kidney transplant recipient].
    Reina Prieto J; Bestard Palmer X; Saurina Gomila J; Gascó Company J; Fernández-Baca Gutiérrez del Alamo V; Munar Roca M
    Rev Clin Esp; 1998 Jan; 198(1):3-6. PubMed ID: 9534340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H; Müller C; Löffler J; Jahn G; Einsele H
    Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients.
    Gerna G; Sarasini A; Lilleri D; Percivalle E; Torsellini M; Baldanti F; Revello MG
    J Infect Dis; 2003 Dec; 188(11):1639-47. PubMed ID: 14639533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of human cytomegalovirus in renal transplantation: comparison of four diagnostic methods: DNA in sera by polymerase chain reaction (PCR), DNA in leukocyte by PCR, pp65 leukocytic antigenemia, and viremia.
    Eckart P; Brouard J; Vabret A; Freymuth F; Guillot M; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 1997 Aug; 29(5):2387-9. PubMed ID: 9270775
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients.
    Niubò J; Pérez JL; Martínez-Lacasa JT; García A; Roca J; Fabregat J; Gil-Vernet S; Martín R
    Diagn Microbiol Infect Dis; 1996 Jan; 24(1):19-24. PubMed ID: 8988759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.